Where Will Sorrento Therapeutics Be in 1 Year?
Sorrento Therapeutics (NASDAQ: SRNE) has been one of the best-performing small-cap biotechs this year: In three months ended June 5, its shares rose by almost 87%. So what does the company have in its pipeline that is generating such enthusiasm among investors?
Currently, the company's pipeline is heavily focused on pain management and is still in early stages of clinical studies. However, investors are largely excited about Sorrento's potential with regard to developing neutralizing antibodies for COVID-19. Upon deeper analysis, it appears neither of the company's pipeline indications is particularly promising, which places Sorrento's stock in a high-risk category.
Image Source: Getty Images.
Source Fool.com
